New Delhi: Pharmaceutical major Ranbaxy Laboratories Ltd has got approval from Drugs Controller General of India (DGCI) to export 10.2 lakh tablets in multiple dosages of anti-psychotic drug quetiapine hemifumarate to the UK.
The company, which sought permission to export quetiapine hemifumarate which is used for treatment of conditions like schizophrenia, was granted a no objection certificate last month by DGCI to export six different strengths of the drug.
In its approval letter to the company, DGCI allowed Ranbaxy to export 3.6 lakh tablets of quetiapine 25 mg, 1.8 lakh tablets of quetiapine 50 mg and 1.2 lakh tablets each of quetiapine 100 mg, 150 mg, 200 mg and 300 mg.
DGCI, however, said in the event of the export order being cancelled, Ranbaxy would be required to destroy the unexported quantity and no part of it would be diverted for domestic sales.
Ranbaxy will manufacture the drug form its Poanta Sahib facility in Himachal Pradesh, according to Malvinder Mohan Singh, the company’s managing director.